Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MOMA-313 |
Synonyms | |
Therapy Description |
MOMA-313 inhibits the helicase domain of DNA polymerase theta (POLQ), which may prevent the repair of DNA double-strand breaks, resulting in decreased tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 1749). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MOMA-313 | MOMA 313|MOMA313 | MOMA-313 inhibits the helicase domain of DNA polymerase theta (POLQ), which may prevent the repair of DNA double-strand breaks, resulting in decreased tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 1749). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06545942 | Phase I | MOMA-313 + Olaparib MOMA-313 | Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | GBR | ESP | 0 |